Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an announcement.
Chimeric Therapeutics announced positive results from its CHM CDH17 Phase 1/2 clinical trial, demonstrating disease control and tumor shrinkage in patients with advanced colorectal cancer and neuroendocrine tumors. The trial’s Safety Monitoring Committee confirmed the safety of Dose Level 2, with patients showing significant tumor reduction and stable disease. These promising outcomes highlight the potential of Chimeric’s CAR-T platform to impact cancer treatment and strengthen its position in the cell therapy industry.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is an Australian clinical stage cell therapy company focused on developing innovative cell therapies for cancer treatment. The company has a diversified portfolio that includes autologous CAR T cell therapies and allogeneic NK cell therapies, with assets being developed across multiple oncology areas. Chimeric is recognized for its pioneering work in cell therapy and is advancing several clinical stage programs.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.76M
Learn more about CHM stock on TipRanks’ Stock Analysis page.